R&D offer
Cetim Carnot Institute : Fatigue Design 2019
Leti Memory Workshop - Grenoble - France
Leti Carnot Institute organize Memory Workshop on eNVM, July 2nd 2018 - Grenoble - France.
This one-day workshop will explore short-term and long-term memory solutions. Industrials and experts will share their views, discuss start-up creation and introduce disruptive concepts that will soon penetrate the market. To expand our horizons, world-class academics will also provide their views on non-conventional applications.
Curie Cancer Carnot Institute names Intel lead partner to implement high performance computing and artificial intelligence in accelerating genome sequencing and interpretation for oncology
Curie Cancer Carnot Institute and Intel initiate a pioneering collaboration to develop, use and implement innovative Bioinformatics tools, pipelines and techniques to improve the use of molecular profiling across both research and clinical oncology settings.
Curie Cancer Carnot Institute and Freenome announce a strategic collaboration in cell-free DNA analysis using machine learning technology
Curie Cancer Carnot Institute and Freenome announce a strategic collaboration to evaluate Freenome’s artificial intelligence (AI) genomics platform as a novel tool to predict patient response to immuno-oncology therapies by observing changes in circulating cell-free biomarkers.
The Leti Carnot Institute at SEMICON Europa 2016 in Grenoble
The Leti Carnot Institute will exhibit at SEMICON Europa 2016 in Grenoble, France, on Oct 25-27.
Learn more about the latest advancements in microelectronics with Leti experts as they discuss through a selection of conferences, forums and sessions.
Register now to download the full program and make the most of the largest microelectronics event in Europe!
CALYM’S 3rd SCIENTIFIC & PARTNERING DAY
CALYM’s 3rd SCIENTIFIC & PARTNERING DAY, will take place next October 17, 2016 in Paris, Espace Van Gogh, 62, quai de la Rapée.
CALYM researchers and clinicians will be happy to present the new lymphoma R&D offering and highlight research results of the consortium, from new therapeutic targets identification to Phase III pivotal clinical trials and beyond.
IPSEN and CELGENE representatives will bring industry standpoint.